Three In A Row: FibroGen's Investigational Drug Flunks In Another Study For Rare Disease In Young Boys
Portfolio Pulse from Vandana Singh
FibroGen Inc's (NASDAQ:FGEN) investigational drug, pamrevlumab, failed to meet the primary endpoint in the Phase 3 LELANTOS-2 trial for Duchenne muscular dystrophy (DMD) patients. This follows the failure of the LELANTOS-1 trial in June and the ZEPHYRUS-1 trial for idiopathic pulmonary fibrosis. Despite the drug being generally safe and well tolerated, the company's shares fell by 22.3% in premarket trading.
August 30, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FibroGen's drug, pamrevlumab, failed in another Phase 3 trial, leading to a significant drop in the company's shares.
The failure of the Phase 3 LELANTOS-2 trial of pamrevlumab, following the failure of two other trials, has negatively impacted investor confidence in FibroGen. This has led to a significant drop in the company's share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100